Anthos Presents New Analysis from P2 AZALEA-TIMI 71 Study

Nov. 16, 2024  Anthos Therapeutics, Inc.recently presented new data at the American Heart Association (AHA) Scientific Sessions from its AZALEA-TIMI 71 study that demonstrated the novel factor XI inhibitor abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, as compared to rivaroxaban.

"Given the elevated bleeding risks associated with traditional anticoagulants, particularly when combined with antiplatelet agents, abelacimab may offer a safer alternative for patients with atrial fibrillation,” said Christian T. Ruff, MD, MPH, senior investigator of TIMI Group and director General Cardiology, Cardiovascular Division, Brigham and Women's Hospital. “These data suggest that abelacimab may potentially be an attractive option for those patients who could benefit from anticoagulation and antiplatelet therapy.”

The data demonstrate a 67% reduction in bleeding for patients on APT taking abelacimab 150 mg compared to patients taking rivaroxaban (a 10.6% incidence rate for rivaroxaban to a 3.5% incidence rate for abelacimab 150 mg).^[1] 

As expected, the absolute rate of bleeding observed was higher when rivaroxaban was combined with APT vs. rivaroxaban alone (10.6% vs. 7.7%).^[2] However, the rate of bleeding in patients treated with abelacimab 150 mg was similar, regardless of APT use (3.5% abelacimab with APT vs 3.1% abelacimab alone).^[3] The absolute risk difference between abelacimab 150 mg and rivaroxaban was also greater in patients on APT compared to those not on APT (7.1% vs 4.6%).^[4]

"Many patients taking antiplatelet therapy are simply not prescribed anticoagulants because of the fear of bleeding, leaving them without protection from the risk of stroke,” said Dan Bloomfield, MD, chief medical officer of Anthos Therapeutics. “The absence of a meaningful increase in bleeding when abelacimab is added to APT as demonstrated in this trial is remarkable and provides further evidence that, if approved, factor XI inhibitors are likely to transform how physicians will approach treating patients who need to be anticoagulated to reduce their risk of stroke.”

AZALEA-TIMI 71 Antiplatelet Therapy Patient Details

• Patient Population: Out of the 1,287 patients enrolled in the study, 318 (25%) were already taking antiplatelet therapy (APT), which is medication to prevent blood clots. APT included either aspirin alone (16%), another type of drug called P2Y12 (7%), or both (DAPT – dual antiplatelet therapy) (2%).
• Patient Demographics: Patients on APT had a higher rate of coronary artery disease (70% vs. 42%), previous heart attacks (36% vs. 16%), and peripheral artery disease (15% vs. 11%).

For more information, please visit anthostherapeutics.com.

References

1-4 TIMI Study Group website, AZALEA 71

5 Goodman SG et al. Crit Pathways in Cardiol 2024;23: 47–57